All News

gene signature RNA

Synovial Tissue Signature Guiding Targeted IL-6 Therapy in RA

d Jack Cush, MD

RNA sequencing and classification of RA subsets has proven useful. RNA sequencing-based stratification of RA synovial tissue showed stronger associations with clinical responses compared with histopathological classification. Additionally, for patients with low or absent B-cell lineage expression signature in synovial tissue, tocilizumab is more effective than rituximab.

Read Article
cardiac2.jpg (keep)

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

d Jack Cush, MD

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,

Read Article
sick kid child temperature fever

IVIg in MIS-C

d Jack Cush, MD

Among children with multisystem inflammatory syndrome (MIS-C), treatment with IVIG and methylprednisolone vs IVIG alone was associated with a more favorable fever course. MIS-C is a rare but serious pediatric condition associated with COVID-19 where different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs.

Read Article
Lknee.OA_.jpg

NSAIDs in Osteoarthritis: Study Suggests Need for New Look

d Jack Cush, MD

Knee osteoarthritis (OA) patients using nonsteroidal anti-inflammatory drugs (NSAIDs) showed greater loss of medial minimum joint space width than did others taking other drugs, registry data indicated.

Read Article

We are excited to announce that Dr. Eric Ruderman ( @JointMD) will be speaking on advancing treatments in psoriatic arthritis at RheumNow Live, March 20-21. There's still time to sign up. https://t.co/vJlU0Z3Q3x https://t.co/T0V8JIygyA

Links:

Dr. John Cush RheumNow ( View Tweet)
Text mining of #EHRs can be used to accurately identify and characterize patients with #SLE #Lupus #Rheumatology #RheumTwitter https://t.co/JayhTRRPz9

Links:

Rheumatology Advisor RheumAdvisor ( View Tweet)

Adherencia a fármacos biológicos subcutáneos en enfermedades inflamatorias (artritis crónicas y enfermedades inflamatorias intestinales). Contento del resultado de nuestr Revisión Sistemática 🦾 @carmona_loreto https://t.co/Elmc61BE6d
Juan Carlos Nieto JCNietoGon ( View Tweet)

Hydroxychloroquine Fails to Prevent COVID-19 The NEJM reports the results of a trial where HCQ given as post-COVID exposure therapy failed to prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons. https://t.co/lt71GAtL3D https://t.co/9OyUpQBpzL

Links:

Dr. John Cush RheumNow ( View Tweet)
402 RA pts in RA-Paz registry, starting bDMARD betw 2000 - 2019, had 10% refractory to multiple biologics. Difficult or multi-biologic refractory Dz predicted by erosions, younger age, high baseline DAS-28, unable to lower DAS < 1.2 @6 mo (OR 11.1) https://t.co/GYJ69dgCtr

Links:

Dr. John Cush RheumNow ( View Tweet)

Between March - Oct 2020, 10 US states with mask mandates reported a 4.9% decline in weekly COVID-19 hospitalizations, significant for those under 65 yrs (5.5%). Results most notable > 3 weeks after the mask mandate. https://t.co/umjiFVNACF

Links:

Dr. John Cush RheumNow ( View Tweet)

Johns Hopkins & UCSF Scleroderma pts tested for Abs against telomerase & shelterin (TERF1); while rare in RA, myositis, controls; TERF1 Abs seen in 9% of SSc & assoc w/ severe lung disease (OR 2.4) & shorter telomere length. (TERF1 found in 7% of IPF) https://t.co/e5ai8uO4kK

Links:

Dr. John Cush RheumNow ( View Tweet)

Abrupt Cessation of Long-Term Opioid Prescribing Common Medicare beneficiaries were increasingly likely to have long-term opioid therapy stopped in recent years and medication changes often were abrupt, not tapered, an observational study showed. https://t.co/bCnaJHECd0 https://t.co/PfM9BCNPyC

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib when given to at-risk RA patients. https://t.co/RJD8CMouHK https://t.co/j8DMyxsaaf

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab, a bispecific mAb inhibits IL-7F & IL-17A, was testedin PhIII trial in Active psoriasis and show to be more effective than ustekinumab and placebo. 567 PSO pts - at wk 16, PASI90 was BMKZ 85% vs Ustekinumab 50%, vs 5% in placeob (p<0·0001) https://t.co/Z4ZQEHO4rX

Links:

Dr. John Cush RheumNow ( View Tweet)

Vagal Nerve Stimulation in Rheumatoid Arthritis Lancet Rheumatology has reported the results of a proof of concept trial, wherein vagal nerve stimulation was shown to ameliorate rheumatoid arthritis (RA) disease activity. https://t.co/XKH0ZY2A7E https://t.co/41nIxMb3e6

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic Podcast from Last week. iTunes https://t.co/FHJv01AAbC or SoundCloud https://t.co/dfSTkSbY2d QD Clinics (123-127; Feb 5) QD127 - Chronic Monarthritis QD126 - Fever by the Numbers QD125 - "What Were You Thinking" QD124 - No Win Consults QD123 - When RA Meets UC https://t.co/ReOFOVooje

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Biobank examined the association between comorbidities & uric acid (SUA). Comorbidities assoc w/ increasing SUA. For each 1 mg increase in SUA, there is a 1-3 fold incr risk of HTN, IHD, CCF, ^HL, CKD https://t.co/ZEPAPRq62k

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! Tofacitinib Safety Concerns - covering vagal nerve stimulation, IL-23 in PsA, Diet & RA, NSAIDs & COVID, Plaquenil side effects and more. Watch it here>> https://t.co/7RDZ0avZLC ListeniTunes>>https://t.co/FHJv01AAbC or SoundCloud>>https://t.co/yJWJNa6CRL

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - Chronic Monarthritis Treatment Considerations on Chronic Monarthritis https://t.co/7VmH1skHhb

Links:

Dr. John Cush RheumNow ( View Tweet)

Download available--30 FDA Approved Biologics in Rheumatology https://t.co/HSvllkDUz7

Links:

Dr. John Cush RheumNow ( View Tweet)

×